| Name | Title | Contact Details |
|---|
Disaster Management Group, LLC is a Stuart, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Hughston Clinic Pc is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Auburn, AL. To find more information about Hughston Clinic Pc, please visit www.hughston.com
UT Medical Group is the private practice arm of the University of Tennessee Health Science Center (UTHSC) faculty. Because the physicians in our group are actively involved in teaching and research, they remain current with the latest medical developments. As a not-for-profit, non-tax-supported group practice, UT Medical Group is dedicated to quality patient care, medical education, and medical research. This allows us to offer many unique, advanced health care services to people in the Mid-South at competitive prices. Ties to UTHSC allow the physicians at UT Medical Group access to the latest treatments, special protocols and labs, as well as a broad spectrum of professionals with advanced degrees in nursing, nutrition, pharmacology, psychology, and more. This involvement benefits not only our patients' treatments, but keeps the physicians at the top of their fields.
Cavapharma is a Kirkland, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.